The Phase III trial follows the company’s previous Phase I trial, which saw 12 participants dosed with Bemdaneprocel. Credit: Shutterstock / Yuri A US-based Bayer subsidiary BlueRock Therapeutics has ...

Credit: Shutterstock / Doucefleur Massachusetts gastrointestinal disease firm, Cristcot, has announced results from its Phase III trial examining its hydrocortisone suppository and applicator for ...

German pharma major Bayer (BAYN: DE) today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms ...

Its rival Moderna said earlier this month, however, that it has already fully enrolled a 6,000-subject phase 3 study of its quadrivalent vaccine candidate mRNA-1010 in the southern hemisphere ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

US pharma giant Pfizer (NYSE: PFE) today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (MAb), in ...

Periplasmic expression with cytometric screening (PECS ... ester and a 3′-FITC were from Integrated DNA Technologies (Coralville, IA) and supplied at reverse-phase high- performance liquid ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. The biotech provided a closer look at the data Tuesday, shutting down one source of hope analysts had clung to after the ...

The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...

according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. "KATHERINE is a landmark clinical ...

The new C-POST Phase III trial, demonstrates the utility of LIBTAYO for adjuvant treatment for high risk patients after surgery, potentially a significant growth prospect to address an unmet need.

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...